Recent study found that a covalent inhibitor (called PBRM) targeting the enzyme (17beta‐HSD1) showed the ability to block the pathway of oestrogen biosynthesis and reduce tumour growth in BC models, with no toxic effects observed.19 Here, HSD17B1 is linked to breast cancer.